Patents Assigned to HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
  • Five-membered-fused six-membered compound, preparation method, pharmaceutical composition and use
    Patent number: 12281098
    Abstract: A five-membered-fused six-membered compound, a preparation method, a pharmaceutical composition, and the use. The penta-fused hexa-heterocyclic compound is a compound represented by formula (II) or (III). The compound has an inhibition or/and degradation effect on IRAK4.
    Type: Grant
    Filed: April 11, 2024
    Date of Patent: April 22, 2025
    Assignee: HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
    Inventors: Jason Shaoyun Xiang, Lei Wu, Rui Xu, Qiang Zhang, Gang Yang, Michael Xiang, Mixue Tong, Camille Xiang, Suyue Wang, Rui Yang
  • Five- and six-membered compound, and preparation method therefor and pharmaceutical composition and use thereof
    Patent number: 12195479
    Abstract: A five-membered-fused six-membered compound, and a preparation method therefor and a pharmaceutical composition and the use thereof. The five- and six-membered compound is a compound as shown in formula I, II or III. The compound has an inhibitory effect on FLT3 and/or IRAK4.
    Type: Grant
    Filed: December 19, 2023
    Date of Patent: January 14, 2025
    Assignee: HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
    Inventors: Jason Shaoyun Xiang, Lei Wu, Rui Xu, Qiang Zhang, Gang Yang, Michael Xiang, Mixue Tong, Camille Xiang, Yuxin Liu, Suyue Wang, Rui Yang
  • Anti-IL-17 antibody/TNFR ECD fusion protein and use thereof
    Patent number: 11667704
    Abstract: The invention relates to the field of medical biotechnology. Specifically, the present invention relates to a fusion protein containing an anti-interleukin-17 antibody and a tumor necrosis factor receptor extracellular region, a polynucleotide encoding the fusion protein, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, and the use of the fusion protein for the treatment, prevention, and/or diagnosis of a related disease in an individual.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: June 6, 2023
    Assignees: BEIJING BEYOND BIOTECHNOLOGY CO., LTD, HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
    Inventors: Pinliang Hu, Jing Zou, Weidong Hong, Yun He, Jie Bai, Lingyun Song, Wendi Yang, Zhijian Lv, Shaoyun Xiang